6CM
ASMB icon

683 Capital Management’s Assembly Biosciences ASMB Stock Holding History

683 Capital Management’s Portfolio ASMB Stock Details ASMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-27,863
Closed -$773K – 163
2026
Q1 		$773K Hold
27,863
– – 0.04% 152
2025
Q4 		$948K Buy
+27,863
New +$897K 0.04% 145

Other funds holding ASMB

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $977M AUM 110.37% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

683 Capital Management's ASMB Position: Q2 2026 in Review

683 Capital Management sold out of Assembly Biosciences (ASMB) in Q2 2026, closing a stake of 27,863 shares — an estimated $773K sold.

683 Capital Management first reported a position in ASMB in Q4 2025 and held it in 2 quarters. The position peaked at $948K in Q4 2025. 93 funds tracked by Wall St. Rank hold ASMB as of Q2 2026.

  • 683 Capital Management reported no remaining Assembly Biosciences position as of Q2 2026 after selling out during the quarter.
  • 683 Capital Management sold 27,863 Assembly Biosciences shares in Q2 2026, an estimated $773K.
  • 683 Capital Management first reported a position in Assembly Biosciences in Q4 2025 and held it in 2 quarters.
  • 683 Capital Management's Assembly Biosciences position peaked at $948K in Q4 2025.
  • 93 funds tracked by Wall St. Rank held Assembly Biosciences as of Q2 2026.

Based on 683 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.